In Italy, the National Prevention Plan 2020–2025 promotes the adoption of organized pathways for the prevention of BC (and ovarian cancer) associated with BRCA1/BRCA2 PGVs, with the activation of a Diagnostic-Therapeutic-Assistance Path called “High Hereditary-Familial Risk for people carrying BRCA pathogenetic variants” [81,82]. This evidence concerns the gene BRCA2 and ovarian cancer.